...1) Assume Biocon receives approval for BIOMab, should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate on the various elements of your action plan. Biocon should launch the drug immediately because a number of obstacles have already been overcome: first being the approval from the regulator as the number one obstacle; second being the very positive outcome of Phase 2 tests on patients with Head and Neck Cancer and; thirdly, it has broken the price barrier by being significantly cheaper for patients by requiring only 6 doses instead of an indefinite number of doses for other drugs. A competing drug Erbitux had already passed phase 3 and would soon be introduced in India. Hence, BIOMab should launch immediately to capitalize on the positive publicity of being the first to launch in India. The channel infrastructure was favorable to Biocon as there were only a few oncology centres in India, which means that it will make phase 3 trials cost effective and relatively easy to monitor. As Biocon also has good relationships with doctors at the cancer centres, we can start the use of BIOMab at the cancer centres very quickly. The next channel to target would be the leading 100 oncologists out of a total of 300 in India. The relatively small size of the channels meant that it would not be too much of a challenge for Biocon’s sales reps. The key advantages of BIOMab would be the straightforward 6 dose treatment cycle which would simplify the process...
Words: 1114 - Pages: 5
...BIOCON – Launching a New Cancer Drug in India Brief Details Biocon who have successfully done the phase 2 trial of their new Cancer drug – Biomab are the first Indian company who have got break through success in the field of Head and neck Cancer drug. They still had to get their phase 3 trial done (which looks like a market norm, though not a legal requirement). Erbitux which was developed by Imclone Systems in US had granted license to Merck to distribute the drug to India. Erbitux had already done 3 phase trial and they have got approval from European and US Drug agencies. They still not have received the approval from India drug authority (DGCI). But the same was expected soon. 1) Launch of BIOMAb Sensing the arrival of Erbitux into the Indian market some of members of Biocon management wanted a fast launch of BioMab. Cancer is a very critical illness and any deficiency in the medicine can be fatal for individuals. So ideally Biocon should first go for 3rd phase trial, check the competency of the product and then go for launch. They should not look for a short term advantage of being first entrant. Since of their product face any rejection (or have any drawback), it can be devastating on the reputation of the company. This can dampen the company’s image which can badly go against them. So it would be a better option for them to complete the 3rd phase trial of the product and then go ahead. Parallely even their marketing strategy was not ready for the product so it made...
Words: 1171 - Pages: 5
...Strategic Management Biocon – Term Paper Name: Naresh.N Section: B Semester : 3rd Batch : 2011-2013 PES Institute of Technology 2012 1/1/2012 INTRODUCTION Industry Biotechnology Founded 1978 Founder(s) Kiran Mazumdar-Shaw Headquarters Bangalore, India Biocon Limited (BSE: 532523) is a global biopharmaceutical company with products and research services ranging from pre-clinical to clinical development through to commercialization.[ref 1] Within biopharmaceuticals, the Company manufactures generic active pharmaceutical ingredients (APIs) like Statins and Immunosuppressants that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar Insulins, which are sold in India as branded formulations and in both bulk and formulation forms. Located with R & D in Bangalore and API unit in Hyderabad, India, Biocon has two subsidiaries— Syngene, a custom research organization, and Clinigene, a clinical research organization. Biocon’s presence straddles four main therapeutic areas—Diabetology, Cardiology, Nephrology and Oncology. History Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. November 29, 1978 Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. 1979—Becomes the first Indian company to manufacture and export enzymes to...
Words: 4681 - Pages: 19
...2012 STRATEGIC MANAGEMENT TERM PAPER ALOK KEJARIWAL 1PI11MBA13 INTRODUCTION Industry Biotechnology Founded 1978 Founder(s) Kiran Mazumdar-Shaw Headquarters Bangalore, India Biocon Limited (BSE: 532523) is a global biopharmaceutical company with products and research services ranging from pre-clinical to clinical development through to commercialization.[ref 1] Within biopharmaceuticals, the Company manufactures generic active pharmaceutical ingredients (APIs) like Statins and Immunosuppressants that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar Insulins, which are sold in India as branded formulations and in both bulk and formulation forms. Located with R & D in Bangalore and API unit in Hyderabad, India, Biocon has two subsidiaries— Syngene, a custom research organization, and Clinigene, a clinical research organization. Biocon’s presence straddles four main therapeutic areas—Diabetology, Cardiology, Nephrology and Oncology. History Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. November 29, 1978 Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. 1979—Becomes the first Indian company to manufacture and export enzymes to USA and Europe. 1989—Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with...
Words: 4668 - Pages: 19
...higher-price-fetching insulin market. Their brand positioning worked well for them as they were the only Bio-tech company that could meet India’s market demand. The company simultaneously developed its marketing strategy and skills from scratch. Also the point-of-difference with their only competitors in India, Novo and Eli Lily, was the 20% to 30% price difference in favor of Biocon. They quickly gained 10% of the Indian market and 25% to 30% of new insulin prescriptions. Anticipating the maturing of the Indian drug market, Bicon developed its growth strategy further. This time they shifted their attention to proprietary drugs. By 2004, Biocon was not only a fully integrated biotech company doing clinical trials, but also an IPO. With the advent of BIOMab, Biocon business strategy evolved further and incorporated inlicencing, partnerships and collaboration with other companies...
Words: 381 - Pages: 2
...|Biocon | Consolidated Financial Performance: | |(Rs. In Crores) | | |2005 |2006 |2007 |2008 |2009 |2010 | |Sales | |Bio Pharmaceuticals |557 |603 |728 |787 |1372 |2036 | |Enzymes |90 |85 |95 |46 |- |- | |Research and Technical Licensing Fees |66 |100 |163 |220 |237 |332 | | | |Total |713 |788 |986 |1054 |1609 |2368 | | | |Other Income |15 |5 |4 ...
Words: 2907 - Pages: 12
...(Cover Page) “PROJECT ON “SUCCESS STORY OF AN ENTREPRENEUR – KIRAN MAZUMDAR” Master of Commerce Semester – III (2014-2015) Submitted In Partial Fulfillment of the requirements For the award of degree of M.Com By Arati Sachidanand Mishra Seat No. _86_ Tolani College of Commerce Sher – E – Punjab society, Andheri (East), Mumbai – 400 093. PROJECT ON “SUCCESS STORY OF AN ENTREPRENEUR – KIRAN MAZUMDAR” Master of Commerce Semester – III (2014-2015) Submitted In Partial Fulfillment of the requirements For the award of degree of M.Com By Arati Sachidanand Mishra Seat No. _86_ Tolani College of Commerce Sher – E – Punjab society, Andheri (East), Mumbai – 400 093. CERTIFICATE This is to certify that Arati Sachidanand Mishra of M.Com. Semester III (2014–2015) has successfully completed the project on “Success Story of an Entrepreneur- Kiran Mazumdar” under the guidance of Prof. Mahalaxmi Ramaprasad. Project Guide: - ___________________ Course Co-Ordinator: - ___________________ External Examiner: - ___________________ Principal: - ___________________ DECLARATION I, Arati Sachidanand Mishra the student of M.Com.Semester III (2014-2015) hereby declare that I have completed the project on “Success Story of an Entrepreneur- Kiran Mazumdar” in the course (Entrepreneurship Management). The information submitted is true and original to the...
Words: 8767 - Pages: 36
...Pharmaceuticals and Life Sciences Global pharma looks to India: Prospects for growth Table of contents Introduction 03 Background 04 A fast growing economy An expanding pharmaceutical market Government-provided healthcare improving, but private healthcare dominates Domestic market overview 09 Background Consolidation underway, despite challenges Contract manufacturing Vaccines Over the counter market holds significant potential Reaching the untapped rural market Growing Research & Development 15 Overview Clinical trials Biotech and biosimilars on track for growth Other growth areas Bioinformatics 20 Stem cell research Medical devices Global Pharma’s evolving business models and options in India 23 Background Export-oriented business (Contract Research and Manufacturing Services) Licensing Franchising Joint ventures Wholly-owned subsidiaries Practical concerns 27 Infrastructure Tax environment Counterfeiting Intellectual property Conclusion 30 Related reading: Pharma 2020 31 References 32 Acronyms 38 Introduction The pharmaceutical industry’s main markets are under serious pressure. North America, Europe and Japan jointly account for 82% of audited and unaudited drug sales; total sales reached US$773 billion in 2008, according to IMS Health. Annual growth in the European Union (EU) has slowed to 5.8%, and sales are increasing at an even more sluggish rate...
Words: 17333 - Pages: 70
